Cara Therapeutics announces dosing of patients in phase 2 trial of oral KORSUVA™
Cara Therapeutics announced the first patients have been dosed in a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for treatment of pruritus in stage III-V (moderate-to-severe) CKD patients. CKD-aP is a condition that affects approximately 25% of pre-dialysis CKD patients. July 11, 2018